Ketanserin (CAS 74050-98-9) is a synthetic compound primarily classified as a serotonin receptor antagonist (with high affinity for 5-HT₂ receptors) and a weak alpha₁-adrenergic receptor blocker. Its applications span clinical medicine, pharmacological research, and limited veterinary use, detailed as follows:
Ketanserin was once used clinically for managing essential hypertension (primary high blood pressure). Its mechanism of action involves:
Blocking 5-HT₂ receptors in blood vessels to inhibit serotonin-induced vasoconstriction, thereby relaxing vascular smooth muscle and reducing peripheral vascular resistance.
Weakly blocking alpha₁-adrenergic receptors, which also contributes to vasodilation and blood pressure lowering.
It is suitable for mild to moderate hypertension, especially for patients with concurrent conditions such as diabetes or hyperlipidemia, as it has a relatively small impact on blood glucose and lipid metabolism.
Due to its vasodilatory effect, ketanserin can be used to treat peripheral vasospastic diseases, such as:
Raynaud’s phenomenon: Relieves vasospasm of the extremities caused by cold or emotional stress, improving symptoms like finger/toe pallor, cyanosis, and pain.
Intermittent claudication: Improves blood supply to the lower limbs in patients with peripheral arterial occlusive disease, reducing exercise-induced leg pain.
Since serotonin plays a key role in the pathogenesis of migraine, ketanserin’s 5-HT₂ receptor blocking effect can help prevent migraine attacks, especially for patients whose migraines are triggered by vasospasm. However, it is not a first-line drug for this indication and is usually used when other preventive medications are ineffective or intolerable.
Ketanserin is a widely used research tool compound in neuroscience and pharmacology, mainly for:
Receptor characterization: As a selective 5-HT₂ receptor antagonist, it is used to identify and validate the role of 5-HT₂ receptors in biological processes (e.g., vascular regulation, neurotransmission, cell proliferation).
Mechanism studies: Investigating the involvement of serotonin in diseases such as hypertension, anxiety, depression, and schizophrenia by blocking specific receptor subtypes.
Drug development: Serving as a reference compound for developing new drugs targeting serotonin or adrenergic receptors.
In veterinary medicine, ketanserin is occasionally used off-label to treat hypertension in companion animals (e.g., dogs and cats) or to alleviate vasospasm-related disorders, but its use is restricted due to limited safety and efficacy data in animals.
China
